Purification method

The adsorption-based purification method using antigen-expressing cells and affinity chromatography effectively purifies antibodies with high specificity for specific antigens, addressing the limitations of existing monoclonal methods and producing pure antibody preparations for diagnostic and therapeutic use.

JP2024161359AActive Publication Date: 2024-11-19QBD QS IP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024111813
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-11-26
Filing Date
2024-07-11
Publication Date
2024-11-19
Estimated Expiration
2036-11-25

AI Technical Summary

Technical Problem

Current monoclonal antibody purification methods fail to selectively purify antibodies specific for certain antigens, particularly blood group antigens, resulting in products with low levels of antibodies capable of binding specific targets, especially for rarer blood group antigens.

Method used

A method involving adsorption-based purification using cells expressing the antigen of interest, followed by isolation of bound antibodies, and subsequent elution and affinity chromatography to obtain antibodies with specificity for a particular antigen.

Benefits of technology

This method allows for the selective purification of antibodies with high specificity and affinity for specific antigens, such as blood group antigens, providing pure antibody preparations suitable for diagnostic and therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161359000005
    Figure 2024161359000005
  • Figure 2024161359000006
    Figure 2024161359000006
  • Figure 2024161359000007
    Figure 2024161359000007
Patent Text Reader

Abstract

To provide a method by which a compound / molecule capable of binding an antigen, such an antibody type compound / molecule, can be purified, extracted, and / or selected.SOLUTION: The method may be used to purify, extract, or select a specific type binding agent from a mixed composition. The method may be used to extract or purify a specific binding agent from a mixed composition that comprises another factor capable of binding another antigen. The method may find particular application as a method for purifying blood group antigen antibody.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention provides methods for the purification of binding agents such as, for example, antibodies, particularly human-derived blood group antibodies. The methods of the invention can be applied to the purification of (polyclonal and monoclonal) antibodies for use in pre-transfusion blood compatibility testing to detect blood type on human red blood cells (erythrocytes) of donor and patient samples. [Background technology]

[0002] It is common practice to purify antibodies prior to use in certain diagnostic systems to reduce non-specific binding caused by contaminating factors and to ensure that concentrated amounts of antibody are present in the test system. For many blood group antigens, there are no monoclonal antibody-expressing cell lines available, therefore obtaining and purifying polyclonal material is required to provide these rare blood group-specific antibodies. Human plasma is rich in various types of proteins, including IgG isoforms that are multispecific to a wide range of different antigens. Current monoclonal purification methods are not sufficiently focused on allowing the extraction of antibodies specific to one antigen. Existing methods will adequately extract or purify all antibodies of the same size / structure from a solution, but will not be able to selectively purify antibodies with specific selectivity or affinity. Purifying polyclonal antibodies using existing monoclonal antibody purification processes will purify most of the antibody types from a sample, certainly all IgG antibodies. This will result in a product that contains antibodies with multispecificity and relatively low levels of antibodies that can bind to specific targets. Thus, if large amounts of specific anti-blood group antigen antibodies are required, prior art monoclonal antibody purification procedures will not produce the required product. Summary of the Invention [Problem to be solved by the invention]

[0003] Therefore, there is a need for procedures for the purification of binding factors (e.g. antibodies, such as polyclonal antibodies) specific for certain antigens, such as blood group antigens present on red blood cells. Furthermore, in the case of antibodies with specificity / affinity for rarer blood group antigens, antibodies with the required specificity are often present in individuals that produce multiple blood group antibodies. It is therefore desirable to provide methods that facilitate or allow the extraction (purification) of specific rarer blood group antibodies from a mixture. [Means for solving the problem]

[0004] The present invention provides a method for purifying, extracting or selecting compounds / molecules that can bind to antigens, such as antibody-type compounds / molecules.The methods described herein may be used to purify, extract or select specific types of binding factors from a mixed composition.For example, the methods may be used to extract or purify specific binding factors from a mixed composition that contains other factors that can bind to other antigens. It will be appreciated that while the methods of the invention can be used to purify, extract or select any type of antigen-binding agent from a mixture, the methods find particular application as methods for purifying, extracting or selecting antibodies, and therefore, for convenience, the invention will be described as relating to the purification, extraction and / or selection of "antibodies." Furthermore, the methods of the present invention can be used to "purify," "extract," or "select" specific antigen binding agents / antibodies from a diverse mixture composition, but for brevity, these and all similar terms are combined under the single term "purify," "purification," and / or "purifying." Accordingly, the present invention will be described hereinafter with reference to a "method of purifying an antibody."

[0005] The term "specific" as applied to binding agents and / or antibodies is intended to encompass binding agents / antibodies that bind to a specific antigen (or epitope thereof). Thus, a "specific" antibody or binding agent may be an antibody or binding agent that binds to a specific antigen (or epitope thereof). Thus, a specific binding agent / antibody may exhibit a certain selectivity, specificity and / or affinity for a specific antigen / epitope. Thus, the method of the present invention provides a method for the purification of specific antibodies, i.e., antibodies that bind to a specific antigen or epitope thereof. Similarly, the phrase "antigen specific for an antibody" refers to an antigen to which a particular antibody binds. The antigen to which a particular antibody binds includes one or more epitopes to which the paratope of the particular antibody binds. The present invention provides an adsorption-based method for the purification of antibodies.

[0006] In a first aspect, the present invention provides a method for purifying an antibody, comprising the steps of: contacting a source of antibodies with a cell expressing the antigen under conditions that allow binding between the antigen and any antibodies in the source; and isolating any bound antibodies. The present invention provides a method comprising: The antibodies purified by the methods of the invention may be specific antibodies, i.e., they bind to a particular antigen or exhibit selectivity, specificity and / or affinity for a particular antigen or epitope thereof. Thus, the antigen expressed by the cells used in the methods of the invention may be specific for the antibody to be purified.

[0007] The present invention therefore relates to a method for purifying a (specific) antibody from a source, comprising the steps of: contacting a source of antibodies with cells expressing an antigen specific for the antibody to be purified under conditions that allow binding between the antigen and any (specific) antibody in the source; isolating any bound antibodies. The present invention further provides a method comprising: The method of the present invention may be viewed as a method for purifying antigen-specific antibodies. Those skilled in the art will recognize that an antigen (e.g., a protein and / or carbohydrate antigen) may contain one or more epitopes. Within any given host, there may be antibodies with specificity for one or more epitopes present on the antigen. Thus, cells for use in the methods described herein may contain the antigens (or at least fragments (including epitopes) of those antigens) to which the antibodies to be purified bind. As described, the products of the methods of the invention are, in effect, antibodies (isolated or purified) that have specificity, selectivity and / or affinity for a particular antigen or epitope. The invention may also be used to purify polyclonal antibodies that all bind to the same antigen, although not necessarily the same epitope on the antigen.

[0008] It should be noted that the term "cell" is used above that the method of the invention may utilize one or more cells. When a population of cells is used, the cells may all be of the same type with the same or similar antigen profile. Alternatively, a population of cells for use in the invention may be a heterogeneous population comprising two or more different cell types. When a population of cells for use is heterogeneous, each cell of the population may exhibit the same or similar antigen profile. Alternatively, the antigen profile of the cells in the population may be diverse and the population as a whole may exhibit the required antigen profile. For convenience, the term "cell or cells" is substituted herein with the term "cell" and thus the term "cell" should be understood to mean one or more cells (e.g. a population of cells). Furthermore, the term "cell expressing an antigen" encompasses not only a single cell expressing one or more particular antigens, but two or more cells (such as a population of cells) that each or collectively express one or more particular antigens. A cell for use in the invention may express and / or harbor an antigen that itself bears or bears within itself an epitope to which the antibody to be purified binds.

[0009] Cells for use may be treated with some method of antigen blocking or neutralization procedure or protocol. For example, one or more of the antigens on the cell surface may be blocked prior to the use of the cells in the methods of the invention. Those skilled in the art will recognize that there are many methods available for blocking antigens, including, for example, the use of binding agents or antibodies that bind and neutralize antigens. The term "neutralize" is used to mean the use of any agent that binds to an antigen and renders it (or any epitope thereof) unable to bind or interact with any other agent. Antibodies can bind to specific antigens / epitopes and such antibodies can be used to neutralize these antigens / epitopes. Thus, cells for use in the methods of the invention may be contacted or treated with a blocking agent, such as an antibody, prior to use. In this way, any given cell may be selectively blocked for one or more antigens expressed by the cell. Additionally or alternatively, cells for use may be treated such that one or more antigens expressed on the surface are unable to be bound by antibodies. For example, the cells may be contacted with an enzyme that removes the epitope or neutralizes or destroys it in some way. All or part of the antigen may be cleaved from the cell surface. The reader should recognize that in either case, the objective is to neutralize only those antigens that bind to antibodies that one is not trying to purify. Antigens that bind to any antibodies one wishes to purify should be left intact so that they are free to bind to the antibody. A blocking procedure or protocol may provide "blocked cells" for use. The use of blocked cells in the methods described herein can improve the selectivity / sensitivity of the methods of the invention, allowing the user to proceed with greater confidence that the method will provide a pure (or substantially pure) preparation of a given binding agent (e.g., any blood group specific antibody).By way of example, if the method of the invention is used to purify specific blood group antigen antibodies, the possibility of contamination of the antibody preparation can be minimized (or perhaps (substantially) eliminated) by first subjecting the cells used to a process or protocol that blocks or neutralizes or destroys antigens / epitopes that may bind to antibodies that are not of interest or that should not be purified. The aim may be to almost completely neutralize the antigen profile of the cells, with the exception of the antigen of interest (e.g. the blood group antigen of interest) that binds to the antibody one wishes to purify.

[0010] The term "cell" may not include cell fragments, such as cell membrane preparations or "stroma". Furthermore, the term "cell" may not include cells of the types described herein conjugated to any form of support. For example, the term may not include cells or altered fragments thereof (e.g., stroma) bound to or associated with any form of polymer (e.g., polymers containing benzenoid nuclei via diazoamino bridges). Thus, the term "cell" may not include cells (e.g., red blood cells) or membranes (e.g., red blood cell membranes) prepared as conjugates.

[0011] The method of the present invention allows for the purification of a specific type of antibody or a specific antibody from any source of antibody.The method may not be used to remove a specific binding agent (e.g., antibody) from a composition (e.g., plasma, serum, or the like).In other words, the method may not be used to remove a specific binding agent (e.g., antibody) from a composition (e.g., plasma, serum, or the like). The source may be a mixed composition that includes multiple types of antibodies as well as other proteins, compounds and molecules. For example, in addition to the antibody of interest (i.e., the antibody to be purified), the source may further include antibodies with specificity or affinity for different antigens / epitopes. Thus, the method of the present invention may be used to purify antibodies specific for a particular antigen from a source with other antigen affinities / specificities.

[0012] The method may be used to purify certain types of antibodies from liquid (mixed) compositions, such as blood and other blood-derived products. For example, the method may be used to purify antibodies from plasma. Additionally or alternatively, the method may be used to purify antibodies from liquid compositions, such as cell culture media. Indeed, one of skill in the art will recognize that the methods described in the present application are applicable to the purification of antibodies from a wide variety of compositions.

[0013] When the method of the present invention utilizes plasma or serum as a source for purifying or extracting antibodies with a certain specificity or affinity, the plasma or serum may be prepared from whole blood using any suitable or standard preparation protocol, or for example, by plasmapheresis. Without wishing to be bound by a particular technique, to prepare plasma, whole blood may be collected and contacted with an anticoagulant. Erythrocytes and platelets may then be removed or separated, for example, by centrifugation. The resulting supernatant is plasma. When using plasma, one may also take into consideration the serological titer of the subject (providing the plasma or from which the plasma is obtained). One skilled in the art will recognize that the more target antibodies (i.e., the antibodies to be purified) present in the serum of the subject, the more antibodies will be obtained by the method of the present invention. Thus, for any given antigen, the method may take into consideration a minimum "serological titer response". This is an indication of how much antibody is circulating against the antigen. A source material obtained from a subject with a serological titer response below a certain threshold is considered not to contain sufficient antibodies.

[0014] The plasma and / or serum for use may be derived from or provided by any suitable subject, including a subject who provides blood (a blood donor), a patient, and / or a subject who has been immunized to produce antibodies against a particular target. Those skilled in the art will recognize that by using serum or plasma as a source of antibodies, a purified polyclonal antibody preparation is obtained. It is understood that although the present invention may be used to purify human antibodies, the methods disclosed herein may be used to purify antibodies from other species, depending on the source. For example, the present methods may be used to purify all mammalian types of antibodies (e.g., bovine, ovine, equine, and rodent antibodies).

[0015] The term "antibody" may include polyclonal and / or monoclonal antibodies. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen or an antigenic derivative thereof. To produce polyclonal antibodies, a host animal, e.g. rabbit, sheep, pig, etc., is immunized (possibly by injection) with a particular antigen (wherein an adjuvant may be added to the antigen). Monoclonal antibodies are homogeneous populations of antibodies with specificity / affinity to or for a particular antigen or epitope thereof. Monoclonal antibodies may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique (Kohler and Milstein (1975), Nature 256:495-497, and U.S. Patent No. 4,376,110), the human B cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV hybridoma technique (Cole et al., 1985, Monoclonal Anti-bodies and Cancer Therapy, Alan R. Liss, Inc., pp.77-96). The method may be used to purify antibodies of any immunoglobulin class, including, for example, IgG, IgM, IgE, IgA, IgD and any subclass thereof.

[0016] The method may be used to purify naturally occurring antibodies, e.g., antibodies with a certain specificity or affinity, produced by a subject and present in the subject's blood and plasma. The method may be used to purify monoclonal antibodies. The method may be used to purify antibody fragments. In such cases, the fragments will contain the antigen-binding portion. Antibody fragments may include Fab fragments, single chain antibodies, and the like. The method may be used to purify chimeric and / or humanized / resurfaced antibodies. In fact, the method may be used to purify any type of antibody (or binding agent). The only requirement is that the antibody, whether an antigen / epitope-binding fragment, monoclonal, natural, polyclonal, humanized, chimeric or synthetic antibody (or even a binding agent in some cases), exhibits a specificity or affinity for an antigen expressed by a cell.

[0017] The cells may be any cells expressing an antigen to which the antibody of interest (the antibody to be purified) binds. The cells may be naturally occurring cells and / or cells modified to express one or more antigens. The cells may be blood cells, e.g. red blood cells (erythrocytes). The cells may be artificial cells created to express an antibody or one or more antigens that bind to the antibody of interest. In addition to "cells", the skilled reader will recognize that other moieties, possibly synthetic moieties, may be used to affect the adsorption step of these methods. For example, a substrate (such as, e.g., beads and the like) coated with a specific antigen (e.g., a specific blood group antigen) may be used. Thus, although the invention has been described by reference to a method utilizing cells, the method may also utilize antigens bound or immobilized to any suitable surface or substrate. In such cases, the method may include an initial step of contacting a source of antibody with an antigen under conditions that allow binding between the antigen and any antibody in the source. The antigen may be immobilized on a suitable surface.

[0018] When the cells used in the method of the present invention are red blood cells, the method may be used to purify antibodies having specificity for a (particular) blood group antigen. Generally, the antibodies are known as "blood group antibodies." Thus, the method described herein may be used to purify blood group antibodies. Accordingly, the present invention provides a method for purifying blood group antibodies, comprising the steps of: contacting a source of blood group antibodies with cells expressing a blood group antigen to which the antibody to be purified can bind under conditions that allow binding between the antigen and the antibody; Isolating the bound antibody The present invention provides a method comprising:

[0019] The term "blood group antibody" as used herein refers to any antibody that has specificity and / or affinity for blood group antigens. A blood group antigen is one of a set of markers present on the surface of red blood cells. These antigen markers are most often used as a means of blood typing. For example, ABO blood typing is based on the presence or absence of "A" and / or "B" type antigens on the surface of red blood cells. Those red blood cells that express antigen type "A" are considered to belong to blood type "A". Those red blood cells that express antigen types A and B are classified as being of type "AB". Red blood cells that lack both A and B antigens are classified as type "O". Furthermore, red blood cells are often classified as either Rh positive or negative. Again, this is dependent on the presence or absence of the Rh ("D") antigen, with cells expressing the "D" antigen being classified as Rh positive. The term "blood group antigen" as used herein includes any antigen (including any of the antigens previously listed herein) classified as belonging to any one of the ABO, MNS, P1Pk, RH, LU, KEL, LE, FY, JK, DI, YT, XG, SC, DO, CO, LW, CH / RG, H, XK, GE, CROM, KN, IN, OK, RAPH, JMH, I, GLOB, GIL, PHAG, FORS, JR, LAN, VEL and CD59 formulas. A complete list of blood group antigen classifications and types can be found at the following website (the entire contents of which are incorporated herein by reference): http: / / www.isbtweb.org / fileadmin / user_upload / files-2015 / red%20cells / links%20tables%20in%20introduction%20text / Table%20blood%20group%20antigens%20within%20systems%20v4.0%20141124.pdf The methods of the present invention may be utilized as a means to purify antibodies that have specificity or affinity for any type of blood group antigen, including the antibodies described herein.

[0020] It should be noted that although the invention has been specifically described with respect to human antibodies, the methods described herein may also be applied to purify antibodies from other species. Indeed, regardless of species, the principle is the same: one needs a source of the antibody to be purified (which may be plasma from an animal) and cells expressing the antigen to which the antibody to be purified binds. The antibodies obtained by the methods of the invention (whether polyclonal or monoclonal) may have various applications. For example, they may have experimental, therapeutic, prophylactic and / or diagnostic utility. These methods of using red blood cells to purify antibodies with specificity / affinity for blood group antigens may yield antibodies applicable for pre-transfusion blood compatibility testing for the detection of blood groups on human red blood cells of donor and patient samples.

[0021] When the antibody source is (human) plasma, it should be understood that plasma is rich in different types of proteins, including IgG isoforms that are multispecific to a wide range of different antigens. Furthermore, antibodies against some of the rarer blood group antigens are often made by individuals that produce multiple blood group antibodies. Therefore, the method of the present invention is particularly useful, as it allows the specific purification of the often rare antibody types among the complexes and heterogeneous mixtures of proteins, antibodies and other compounds that are plasma.

[0022] Current antibody purification systems are optimized for purifying monoclonal antibodies or extracting antibody subclasses from, for example, plasma donations. One skilled in the art will recognize that plasma contains antibodies against a whole class of diverse targets, e.g., plasma may contain antibodies specific to antigens present on pathogens (e.g., antibodies present may be anti-rubella, anti-influenza, etc.). Prior art purification procedures are either inappropriate for polyclonal antibody purification or fail to yield a product containing specific antibodies (i.e., a product containing antibodies specific for a particular antigen); instead, the product may contain all antibodies of similar type / structure present in the source.

[0023] The present invention is an improvement over prior art monoclonal antibody purification methods, which are not sufficiently focused on enabling the extraction of antibodies specific to one antigen, but rather affect the purification of all antibodies of the same size / structure. For example, application of existing monoclonal antibody purification protocols to the purification of polyclonal antibodies from patient plasma will result in the purification of all types of IgG from the sample, resulting in a solution with multiple antibody specificities and relatively low levels of the desired specific antibodies. A further advantage of the present invention is that it is a rapid method for obtaining antibodies that bind (or exhibit specificity) to an antigen. The method described herein is likely cheaper and simpler than any prior art method for generating monoclonal antibodies with a desired specificity. In the field of antibodies with specificity for red blood cell (RBC) type antigens, this is particularly important when not all blood group antigens (such as those that need to be tested by the MosaiQ™ device) have corresponding antibodies available from expressing cell lines. Thus, purification of polyclonal antibodies is required. Thus, the methods of the present invention provide antibodies for use in diagnostics, blood typing testing, donor / patient cross-matching, the MosaiQ™ platform and research.

[0024] By first contacting a source of antibodies with cells expressing a particular antigen, it is possible to extract or purify only those antibodies that have specificity and / or affinity for this particular antigen. A further advantage of using red blood cells (erythrocytes) in purifying blood group antibodies is that the antigen profile of the red blood cells is substantially limited to a profile that includes blood group antigens, and therefore there are no other antigens that can bind to undesired antibodies. Furthermore, it is possible to identify red blood cells with almost any combination of antigens (i.e., it is possible to identify red blood cells with almost any "antigen" profile). Thus, one or more red blood cells that exhibit one or more required antigens can be selected. In this way, the user can have some control over the antibodies to be purified by careful cell selection. For example, if an antibody with a single blood group antigen specificity is desired, the user needs to select red blood cells that exhibit the appropriate blood group antigen profile, preferably red blood cells that express only the antigens to which the antibody of interest binds.

[0025] As described, the antibody source and the cells are contacted under conditions that allow any antibody in the source specific for an antigen of the cells to bind to the antigen. The conditions may be set to allow the antibody present in the source to adsorb to the antigen present on the cell surface. These conditions may include a period of incubation of the cells and the source. For example, the cells and the source may be contacted together for a predetermined time and / or at a predetermined temperature. After contact (or incubation), the antibody / cell complex may form an antibody / cell complex that includes the antibody bound to the antigen on the cell surface.

[0026] Any antibody / cell complexes may be separated from the source by any suitable means. For example, after contacting the cells with the source, the cell / source mixture may be subjected to a mechanical separation technique such as centrifugation. Those skilled in the art will recognize that centrifugation will affect the separation of any antibody / cell complexes from the liquid phase of the source and / or other components of the source, such as proteins, carbohydrates, or other components of the source that are not bound to the cells. If the source is a liquid source (e.g. plasma), after any mechanical separation step (e.g. centrifugation), the supernatant may be removed in a manner that does not disrupt any pellet formed during centrifugation, i.e. the pellet containing the pelleted cell / antibody complexes. The pellet may be subjected to a washing procedure, e.g. by adding a large amount of a suitable diluent (e.g. saline) to resuspend the pellet and again subjected to some form of separation procedure. The washing protocol may be repeated one or more times.

[0027] To isolate and ultimately purify the antibody, the bound antibody (i.e., the antibody adsorbed to the surface of the cells) is dissociated or eluted. Any one of a number of suitable dissociation / elution procedures may be used, such as, for example, warming, extreme temperatures (rapid freeze / thaw), ultrasonic bath, cell lysis, low pH (acid elution / dissociation), cold acid, organic solvents, xylene, chloroform, modified warming (and agitation) and elution / dissociation using chloroquine diphosphate. By way of example, the antibody / cell complex (which may be present in the washed pellet) may be contacted with an elution buffer. The elution buffer may be formulated to effect dissociation of the antibody from the cells. The elution buffer may be formulated to effect antibody dissociation by acid elution (low pH). Suitable elution techniques and / or buffers will be known to those skilled in the art. For example, suitable elution techniques may be used to aid in the diagnosis of autoimmune hemolytic anemia (AIHA), the diagnosis of ABO hemolytic disease of the fetus and newborn (HDFN), identifying the specificity of antibodies when multiple antibodies are present in patient serum or plasma, and phenotyping red blood cells from direct antiglobulin test (DAT) positive patients. Further information regarding suitable elution techniques is available in "Elution techniques in blood bank"; 2006, Roberts, Continuing Education Topics & Issues; (see http: / / www.americanmedtech.org / files / step_online_articles / 301.pdf), the entire contents of which are incorporated by reference. A representative elution buffer may, for example, comprise, consist essentially of, or consist of glycine-HCl and NaCl. The antibody / cell mixture may be incubated for a period of time under any dissociation or elution protocol and then subjected to any protocol or process designed to stop or neutralize any elution or dissociation process / buffer.

[0028] After the elution / dissociation step is completed (and stopped / neutralized), the cell-antibody mixture may be subjected to some form of separation process. For example, the antibody / cell mixture may be centrifuged to obtain a pellet and a supernatant. The supernatant may contain the dissociated / eluted antibodies and may therefore be removed and stored.

[0029] The dissociated / eluted antibodies (which may be present in the supernatant) may then be subjected to a process, in particular to remove, bind or fix the antibodies (e.g., the antibodies present in the supernatant). For example, the supernatant may be subjected to an affinity chromatography process. Any suitable affinity chromatography process may be used, and these processes suitable for antibody purification are well known to those skilled in the art. For example, a protein G column may be used. Briefly, the preparation containing the antibodies (e.g., the supernatant) may be introduced into and passed through a suitable affinity purification column. After an optional washing procedure, the bound antibodies may be eluted from the affinity purification column and collected as an eluate. The eluate may be subjected to further washing, concentration and / or dialysis procedures to obtain the antibody preparation for use. Affinity-based purification methods (with subsequent concentration and / or dialysis steps) may be used to not only obtain purified and / or concentrated antibody preparations, but also to ensure the removal of any contaminants, e.g. contaminants released by cell lysis during elution.

[0030] It is to be understood that the antibody preparation prepared by the method of the invention comprises, consists of, or consists essentially of antibodies having a single specificity and / or affinity, i.e., specificity and / or affinity for a particular antigen. Where the method utilizes red blood cells (erythrocytes) expressing a particular blood group antigen, the antibodies obtained using the protocol of the invention may be blood group antibodies having affinity and / or specificity for this blood group antigen. Depending on the antibody source used, the antibodies may be polyclonal and / or monoclonal.

[0031] In view of the above, the present invention provides a method for purifying an antibody, comprising the steps of: contacting a source of antibody with cells expressing an antigen specific to the antibody to be purified under conditions that allow binding between the antigen and the antibody in the source to form an antibody / cell complex; dissociating the antibody from the antibody / cell complex; and Purifying dissociated antibodies The present invention provides a method comprising: Prior to dissociation of the bound antibody, any antibody / cell complexes may be separated from other components of the source, for example, by centrifugation. After centrifugation, the supernatant is discarded and the pelleted antibody / cell complexes may be washed one or more times. As mentioned, dissociation (of cell-bound or adsorbed antibodies) may be performed by using any form of dissociation / elution protocol, which may include the use of an (acidic) elution buffer.

[0032] Prior to purification of the dissociated antibody, the dissociated antibody may be separated from the cellular material by centrifugation. After centrifugation, the supernatant may contain the eluted / dissociated antibody for purification. As described, purification of the dissociated antibodies may be achieved by using affinity chromatography-based techniques. Antibodies purified by the methods described in the invention may be characterized by any suitable qualitative / quantitative process, such as, for example, HPLC and / or gel electrophoresis. In a further aspect, the invention provides a kit for the purification of an antibody, comprising cells (or e.g. beads or other similar objects) containing / expressing an antigen specific for the antibody to be purified. The kit may comprise blood cells (or e.g. beads or other similar objects) containing / expressing one or more specific blood group antigens. The kit may further comprise a suitable diluent, elution / neutralization buffer (e.g. acid elution buffer as described herein), affinity chromatography materials and instructions for use. The invention will now be described in detail with reference to the following figures: [Brief description of the drawings]

[0033] [Figure 1-1] 1 is a table showing the layout of a source plate for slide printing. [Figure 1-2] 1 is a table showing the layout of a source plate for slide printing. [Figure 1-3] 1 is a table showing the layout of a source plate for slide printing. [Figure 1-4] 1 is a table showing the layout of a source plate for slide printing. [Figure 2-1] 13 is a schematic of the placement of the applied spots per miniarray. [Figure 2-2] 13 is a schematic of the placement of the applied spots per miniarray. [Diagram 3] Chromatograms of polyclonal anti-D and polyclonal anti-K affinity purification experiments. [Figure 4-1] These are images obtained from the assay results of slides 1 to 4 (sample diluent: 2% BSA / PBS containing 4% dextran and 4% PEG). [Figure 4-2] These are images obtained from the assay results of slides 1 to 4 (sample diluent: 2% BSA / PBS containing 4% dextran and 4% PEG). [Figure 4-3] These are images obtained from the assay results of slides 1 to 4 (sample diluent: 2% BSA / PBS containing 4% dextran and 4% PEG). [Figure 4-4] These are images obtained from the assay results of slides 1 to 4 (sample diluent: 2% BSA / PBS containing 4% dextran and 4% PEG). [Figure 5-1] FIG. 1 shows the results for all wells of the assay. [Figure 5-2] FIG. 1 shows the results for all wells of the assay. [Figure 5-3] FIG. 1 shows the results for all wells of the assay. [Figure 5-4] FIG. 1 shows the results for all wells of the assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] [Example] Experimental Results Introduction Not all red blood cell (RBC) type antigens (including the RBC type antigens required for testing by the MosaiQ™ device) have corresponding antibodies available from expressing cell lines. Thus, purification of polyclonal antibodies is necessary. Current purification methods are insufficient due to the presence of multiple antibody classes in plasma (such as human plasma), including IgG isoforms that are multispecific for multiple antigens. Efficient methods for purification of antibodies, particularly blood type antibodies, and specifically polyclonal antibodies, are needed. The objective of the experiments detailed in this example was to purify polyclonal antibodies from patient plasma by a method utilizing adsorption techniques, a low pH elution procedure and (IgG) affinity purification. In this large-scale experiment, 25 mL of polyclonal plasma was used, and specificity of the purified fractions was also assessed on slides using a current manual antigen determination assay.

[0035] material and method Polyclonal adsorption and low pH elution procedure Plasma containing anti-D was incubated with RhD-positive red blood cells at 50% hematocrit in a 2:1 ratio (50 mL plasma: 25 mL cells) for 1 h at 37°C. a The same procedure was performed for plasma containing red blood cells with the corresponding red blood cells. It should be noted that higher hematocrits may be utilized, such as about 55%, about 60%, about 65%, about 70%, about 75% or about 80% cells. Further alternative plasma to cell ratios may be used. For example, the plasma to cell ratio may be about 3:1 or about 4:1. If the red blood cells have a hematocrit of more than about 50%, the plasma to cell ratio may be more than about 2:1.

[0036] After adsorption, elution of the antibodies bound to the erythrocytes was carried out. Prior to incubation, the erythrocyte solution was washed six times with saline to extract hemolyzed cells (3000 rpm, 5 min, acceleration: 9, deceleration: 3). · The cells were then incubated in a 2:1 volume (50 mL elution buffer: 25 mL cells) for 2 minutes at room temperature. Add neutralization buffer + 154 mM NaCl (10% of the cell mixture volume) and mix, then centrifuge at 2000 x g for 60 seconds. The supernatant was removed and transferred to a clean test tube. In preparation for Protein G affinity purification, the eluate was concentrated to 5 mL and diluted 1:10 with Protein G binding buffer.

[0037] Judgment criteria: Prior to initiation, red blood cells may be tested for efficacy and specificity. Red blood cell availability criteria Reacts with homozygous and heterozygous cells (i.e. cells can be selected regardless of the level of antigen expression (strong (homozygous) or weak (heterozygous)) and still bind to the antibody) Selecting cells that express an antigen of interest. Cells for use may be of limited or restricted specificity, i.e., they may express the antigen of interest but lack other antigens that are not of interest. Red blood cells may be at 50% hematocrit as determined by a validated analyzer or specified at the time of donation. Ideally, cells should be less than 4 weeks old.

[0038] Purification by AKTA The AKTA Pure method involved affinity purification over two consecutive IgG protein Gi Hi Trap columns in triplicate at positions 1, 2 and 3. The method involved sequential equilibration of the columns and upflow elution. Samples were injected through the sample loop. During sample loading, the flow rate was reduced to 0.1 mL / min. Table 4: Inlets for affinity purification JPEG2024161359000001.jpg30166

[0039] Protein G columns (column positions 1, 2 and 3) were equilibrated with 5 mL of ELIX H2O followed by 25 mL of Protein G binding buffer prior to use. The general experimental method is shown in Table 5. Table 5: Protocol details for affinity purification. Immediately after detection of the JPEG2024161359000002.jpg47167 peak, a 0.5 mL aliquot was aliquoted into a 96 deep-well plate containing 50 μL of neutralization buffer.

[0040] Due to the low pH of the elution buffer (0.1 M glycine pH 2-3), immediate buffer exchange was required after purification, which was performed using a Zeba desalting column. Identification of peak fractions was performed by AKTA UV traces and total protein levels.

[0041] Judgment criteria - 1ml / min during affinity purification process -1 A constant flow rate of 0.01 and a pressure of less than 0.5 MPa were maintained. Standard sample load / column wash / elution phases were clearly defined in the UV chromatogram of the AC process.

[0042] Sample concentration After affinity purification, 1 mL of the IgG fraction from each specificity was pooled and concentrated 5-fold to a volume of 200 μL (measured per IFU) using Ultracel centrifugal filters.

[0043] Fractions printed onto the array Table 6: Concentration of probes printed on antigen determination array After affinity purification, the purified polyclonal antibodies were printed onto epoxy silane slides at the concentrations shown in Table 6. Anti-D (ESD1 V140550 B01), anti-Fy (ESD1 V140550 B01), and anti-Fy (ESD1 V140550 B01) were used as assay controls and to provide a grid layout for easy image analysis. a (DG-FYA-02, J25541 B01) and anti-K (MS56 J25922 B01).

[0044] Slides were printed with the antibodies listed in Table 6 in a 16 miniarray format. Each miniarray consisted of a 12x12 rectangular grid. This was achieved with 8 source visits and 4 drops per spot. To check for crosstalk (between print head nozzles) and carryover (between source plate visits) during slide printing, 50% glycerol / PBS was printed in alternating rows of the probe grid (Figures 1 and 2). Any positive reaction at these probe sites would highlight either a malfunction of the print head or printing of antibodies at a very high concentration. To suppress carryover, five print heads and a Jetspyder cleaner were used, as well as an integrated wash dish (filled with Arrayjet buffer). Slides were stored in the slide holder at 2-8°C in the dark for 5 days prior to the assay. Figures 1 and 2 show the layout of the source plate and the layout of the resulting prints (placement of spots).

[0045] Judgment criteria The slides and spots were visually checked for successful printing.

[0046] Example method An example of a method for the purification of polyclonal antibodies is provided below. JPEG2024161359000004.jpg128170

[0047] Further representative methods according to the present invention may be summarized as follows. Prior to processing, donor red blood cells are washed three times with 0.9% saline (3500 RPM, 5 minutes, acc: 9, dec: 7). · Plasma is incubated with red blood cells at 70% hematocrit in a ratio of 3:1 (plasma:cells) for 1 hour at 37°C with gentle shaking every 15 minutes. Next, centrifuge the red blood cell / plasma solution (3500 RPM, 5 minutes, acc: 9, dec: 7) and remove the supernatant without disturbing the red blood cell pellet. The supernatant is then replaced with saline. · The solution is then centrifuged (3500RPM, 5 minutes, acc:9, dec:7). The washing protocol is repeated a total of six times. After the final wash, remove the supernatant. The compressed cells are then mixed with elution buffer in a 2:1 ratio (elution buffer:cells) (elution buffer is 0.1 M glycine-HCl, pH 2.7 + 154 mM NaCl). This mixture is then incubated at room temperature for 2 minutes. Next, neutralization buffer (1M Tris-HCl, pH 9.0 + 154 mM NaCl) is added to the cell mixture to make 5% of the total volume of the elution buffer. The solution is then mixed gently and centrifuged at 3500 RPM for 5 minutes (acc: 9, dec: 7). The supernatant is then transferred to a clean container, the pH measured, and any further adjustments made to bring the pH to 7. · Dilute the supernatant 1:1 with Protein G Binding Buffer. Equilibrate the Protein G column with binding buffer. The eluted antibody / binding buffer solution is injected into the chromatography column at a slow flow rate while maintaining constant pressure. After loading the sample, wash the column with 10 column volumes of binding buffer to wash away any unbound antibody or contaminating proteins. Next, 10 column volumes of Protein G elution buffer are applied upflow through the column to elute the bound antibody. The eluted antibody is then concentrated by dialysis into PBS. · Recover eluted antibodies for characterization (gels and serology). The concentrated antibodies are then diluted in PBS + 50% glycerol and printed onto the epoxy silane surface, after which binding is examined using manual antigen titration and positive and negative cells.

Claims

1. 1. A method for purifying an antibody, comprising: contacting a source of antibodies with a cell expressing the antigen under conditions that allow binding between the antigen and any antibodies in the source; and isolating any bound antibodies. The method includes:

2. The method of claim 1, wherein the antibodies to be purified are specific or exhibit selectivity, specificity and / or affinity for cellular antigens or epitopes thereof.

3. The method of claim 1 or 2, which uses one or more cells expressing one or more antigens.

4. 4. A method according to any one of claims 1 to 3, which uses cells expressing or harbouring an antigen that has an epitope to which the antibody to be purified binds.

5. The method of claim 1 , wherein the source is a mixed composition.

6. 6. The method of any one of claims 1 to 5, wherein the source is blood, blood products, serum and / or plasma.

7. 7. The method of claim 6, wherein the blood, blood products, plasma and / or serum is derived from or provided by a subject willing to donate blood (blood donor) and / or a subject immunized to produce antibodies against a specific target.

8. The method of any one of claims 1 to 7, wherein the antibody is a monoclonal or polyclonal antibody.

9. The method of any one of claims 1 to 8, wherein the cells are red blood cells.

10. The method of claim 1 , wherein the cells are not conjugated to a support, support matrix or polymer.

11. The method according to any one of claims 1 to 10, which does not utilize cell membrane fragments or stroma.

12. 10. The method of claim 9, used to purify antibodies having specificity for a blood group antigen or for a particular blood group antigen.

13. 1. A method for purifying blood group antibodies comprising the steps of: contacting a source of blood group antibodies with cells expressing a blood group antigen to which the antibody to be purified can bind under conditions allowing binding of the antigen and the antibody; Isolating the bound antibodies The method includes:

14. 14. The method of any one of claims 1 to 13, wherein the step of isolating the bound antibodies involves dissociating and / or eluting the antibodies adsorbed or bound to the surface of the cells.

15. 15. The method of claim 14, wherein the dissociation / elution procedures include the use of warming, rapid freeze / thaw, ultrasonic bath, cell lysis, acid-based elution / dissociation, chilled acid, organic solvents, xylene, chloroform, modified warming / agitation and chloroquine diphosphate.

16. 16. The method of claim 14 or 15, wherein the step of isolating the bound antibody involves the use of an elution buffer, and the antibody / cell complexes (which may be present in the washed pellet) may be contacted with the elution buffer.

17. 17. The method of claim 16, wherein the elution buffer is formulated to effect dissociation of the antibody by acid elution.

18. 18. The method of claim 16 or 17, wherein the elution buffer comprises, consists essentially of, or consists of glycine-HCl and NaCl.

19. 19. The method of any one of claims 1 to 18, wherein the cells are subjected to an antigen blocking or neutralization process or protocol prior to use.

20. 20. The method of claim 19, wherein the antigen blocking or neutralization process or protocol blocks or neutralizes antigens that may bind to antibodies that are not being purified.

21. 21. The method of claim 19 or 20, wherein the antigen blocking or neutralizing process or protocol uses an antibody as a blocking or neutralizing agent.

22. 1. A method for purifying an antibody, comprising: contacting a source of antibody with cells expressing an antigen specific to the antibody to be purified under conditions that allow binding between the antigen and the antibody in the source to form an antibody / cell complex; dissociating the antibody from the antibody / cell complex; and Purifying the dissociated antibody The method includes:

23. A kit for the purification of an antibody comprising cells containing / expressing an antigen specific for the antibody to be purified.

24. 24. The kit of claim 23, wherein the cells are red blood cells expressing one or more specific blood group antigens.

25. 25. The kit of claim 23 or 24, further comprising a diluent, an elution / neutralization buffer, affinity chromatography materials and / or instructions for use.

Citation Information

Patent Citations

  • Blood samples or stroma bonded through a diazoamino bond to a polymer

    CA1144858A

  • Test for diagnosis

    JP1987088963A

  • A novel parasitic helminth protein

    JP1996505772A

  • Apparatus and method for simultaneously determining blood group antigens

    JP2009513939A

  • Method for preparing antibody dissociated solution from erythrocyte

    JP2010060416A